Should Cancer Trial Eligibility Become More Inclusive?

A new analysis published in Clinical Cancer Research suggests that patients with treatment-refractory cancers who did not meet eligibility criteria for a pan-cancer clinical trial but received waivers allowing them to participate had similar outcomes to patients who participated without waivers. The study highlights the potential benefits of broadening eligibility criteria for clinical trials. However, it remains unclear how increasing trial inclusivity might impact treatment safety and efficacy. The study had limitations, including the small sample size of waiver-granted patients, and experts caution against overemphasizing efficacy based on the results. [Extracted from the article]